Development of an optimal lidocaine infusion strategy for neonatal seizures
- 12 May 2006
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 165 (9) , 598-604
- https://doi.org/10.1007/s00431-006-0136-x
Abstract
Lidocaine is an effective drug for the treatment of neonatal convulsions not responding to traditional anticonvulsant therapy. However, one of the side-effects is a risk of cardiac arrhythmias. The aim of this study was to develop an optimal dosing strategy with minimal risk of cardiac arrhythmias.As a first step, we studied 20 neonates during routine treatment of neonatal seizures with lidocaine. All were given a loading dose of 2 mg/kg in 10 min, followed by the continuous infusion of 6 mg/kg per hour for 12 h, 4 mg/kg per hour for 12 h and finally 2 mg/kg per hour for 12 h. Effectiveness, cardiac toxicity and lidocaine plasma concentrations were then determined.No cardiac arrhythmias were observed, and lidocaine was effective in 76% of the treatments. In most of the treatments (13 out of 20) maximal lidocaine plasma concentrations were >9 mg/L. Plasma levels >9 mg/L have been related to cardiac toxicity when used as an anti-arrhythmic drug in adults. It was of interest that all preterm infants showed high lidocaine plasma levels. Secondly, we developed the optimal dosing regimen, which was defined as an infusion regimen at which maximal lidocaine plasma concentrations are <9 mg/L. Simulations with the developed pharmacokinetic model indicated a reduction in the infusion duration of lidocaine at 6 mg/kg per hour from 12 to 6 h. Thirdly, the new lidocaine dosing regimen was evaluated. Fifteen neonates (16 treatments) were studied. No cardiac arrhythmias were observed, and lidocaine was effective in 78% of the treatments. In most of the treatments (11 out of 16) maximal lidocaine plasma concentrations were <9 mg/L. Again preterm infants showed relatively high lidocaine plasma levels.A new lidocaine dosing schedule was developed. This new regimen should have a lower risk of cardiac arrhythmias and appears to be as effective in term infants. For preterm infants the optimal regimen needs to be determined.Keywords
This publication has 19 references indexed in Scilit:
- Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver functionClinical Pharmacology & Therapeutics, 2004
- Neonatal Mydriasis: Intravenous Lidocaine Adverse ReactionJournal of Child Neurology, 2002
- Lidocaine and SeizuresTherapeutic Drug Monitoring, 2000
- Therapeutic drug monitoring: antiarrhythmic drugsBritish Journal of Clinical Pharmacology, 1998
- Lidocaine for treatment of severe seizures in newborn infants. II. Blood concentrations of lidocaine and metabolites during intravenous infusionActa Paediatrica, 1992
- Adult Respiratory Distress Syndrome following Administration of LidocaineChest, 1982
- Clinical Pharmacokinetics of LignocaineClinical Pharmacokinetics, 1978
- Anti-arrhythmic effects of lidocaine metabolitesAmerican Heart Journal, 1974
- The convulsant potency of lidocaine and its N-dealkylated metabolites.1973
- Effect of Lidocaine on Ventricular Arrhythmias in Patients with Coronary Heart DiseaseNew England Journal of Medicine, 1967